TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Sept. 27, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on September 24, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 336 shares of its common stock and an aggregate of 218 restricted stock units to 1 employee, each as a material inducement for the employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.
馬薩諸塞州安多弗，2024年9月27日 /美通社/ -- transmedics集團公司（"TransMedics"）（納斯達克：TMDX），一家正在改變器官移植治療方式的醫療科技公司，針對患有晚期肺部，心臟和肝臟功能衰竭的患者，今天宣佈於2024年9月24日向1名員工授予336股普通股的非合格股票期權，並授予218個受限制的股票單位，作爲員工加入TransMedics公司就職的重要誘因。這些授予獲得了TransMedics董事會薪酬委員會的批准，並根據納斯達克上市規則5635(c)(4)和TransMedics集團公司引誘計劃的規定進行了授予。
TransMedics granted non-qualified stock options to purchase 336 shares of TransMedics' common stock and 218 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $156.00, the closing price of the common stock on the Nasdaq Global Market on September 24, 2024. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the Company through the applicable vesting date. The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.
TransMedics授予購買336股TransMedics普通股和218個受限制的股票單位的非合格股票期權。這些股票期權的行權價格爲每股156.00美元，即2024年9月24日納斯達克全球市場普通股的收盤價。每個期權所涉及的股份的25％將在員工開始就職日期首個年度紀念日時解鎖，其餘股份將在隨後的三年內以相等的月供方式解鎖，前提是員工在適用的解鎖日期通過與公司的繼續服務。這些期權有10年期限，並受TransMedics集團公司引誘計劃的條款約束。每個受限制的股票單位獎勵的25％將在員工開始就職日期的頭四個週年紀念日解鎖，前提是員工在適用的解鎖日期通過與公司的繼續服務。這些受限制的股票單位受TransMedics集團公司引誘計劃的條款約束。
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
關於transmedics group，inc。
transmedics是世界上便攜式體外溫熱灌注和評估供體器官移植的領先者。該公司總部位於美國馬薩諸塞州安多弗，旨在解決器官移植的需求問題，開發出了保存器官質量、評估器官移植前的可能性和潛在增加供體器官利用率的技術，用於治療終末心臟、肺和肝功能衰竭。
Investor Contact:
Brian Johnston
332-895-3222
[email protected]
投資者聯繫人：
Brian Johnston
332-895-3222
[email protected]
SOURCE TransMedics Group, Inc.
資料來源：transmedics group，inc。
